外周T细胞淋巴瘤的分子分型与预后标志物识别
该研究用定制NanoString平台检测105例外周T细胞淋巴瘤(PTCL)的208个基因,并对76例进行62基因突变分析。结果显示不同组织学类型有特定基因表达谱,RHOAG17V突变在AITL约34.09%、PTCL-TFH约16.66%而PTCL-NOS未检出(P<.0001),B细胞基因表达为AITL的IPI独立预后因素。
要点
- 基因表达谱可区分AITL、PTCL-TFH与PTCL-NOS三种亚型
- RHOAG17V突变在AITL频率约为PTCL-TFH的两倍,PTCL-NOS未检出
- B细胞基因表达是AITL独立于IPI的预后因素
核心结论
- 研究支持并验证PTCL分为AITL、PTCL-TFH和PTCL-NOS三类的现行划分。
- 识别出可用于更精确诊断的标志物基因集。
- B细胞基因表达被认定为AITL独立于IPI的预后因素。
研究设计与样本
- 采用定制NanoString平台分析105例PTCL病例,包含208个与T细胞分化、癌基因、抑癌基因、失调通路及基质细胞亚群相关的基因。
- 使用靶向62个基因的定制panel对76例分布于AITL、PTCL-TFH和PTCL-NOS的病例进行突变谱分析。
主要发现
- 各组织学类型(AITL、PTCL-TFH、PTCL-NOS)与特定基因集相关,包括TFH标志物、细胞毒标志物及滤泡树突细胞、肥大细胞等细胞亚群替代基因和NF-κB等通路基因。
- RHOAG17V突变在三类结节性PTCL间差异显著(P<.0001),AITL为34.09%、PTCL-TFH为16.66%,PTCL-NOS未检出。
- 多因素分析识别出可将病例分层为不同风险组的基因集。
关键数值与推荐
- RHOAG17V突变频率:AITL 34.09%,PTCL-TFH 16.66%,PTCL-NOS未检出,组间P<.0001。
- 5年总生存率约30%。
临床怎么用
- 可借助特定基因表达标志物提高PTCL亚型诊断精确性。
- RHOAG17V突变检测有助于区分AITL与PTCL-TFH。
- B细胞基因表达可用于AITL风险分层,独立于IPI。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-κB) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOAG17V mutations (P < .0001), which were approximately twice as frequent in AITL (34.09%) as in PTCL-TFH (16.66%) cases but were not detected in PTCL-NOS. A multivariate analysis identified gene sets that allowed the series of cases to be stratified into different risk groups. This study supports and validates the current division of PTCL into these 3 categories, identifies sets of markers that can be used for a more precise diagnosis, and recognizes the expression of B-cell genes as an IPI-independent prognostic factor for AITL.
引用
- Rodríguez M, Alonso-Alonso R, Tomás-Roca L, et al. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv. 2021. PMID: 34592752. doi:10.1182/bloodadvances.2021005171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。